Major Depressive Disorder (MDD) Clinical Trials

21 studies are recruiting for major depressive disorder (mdd) in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. Pattern Separation in Major Depressive Disorder

   This study seeks to examine the effects of treatment with a selective serotonin reuptake inhibitor (SSRI), escitalopram, a first-line treatment for depression, in combination with placebo or with extended-release memantine, on neuropsychological function, regional brain activity assessed by functio…

   Stage

   Phase 1

   Ages

   18 to 50

   Site

   New York State Psychiatric Institute (NYSPI), New York, New York

   Run by

   Jeffrey Miller

   See if you can join NCT07139834 on ClinicalTrials.gov

2. Spaced Transcranial Direct Current Stimulation for Treatment-Resistant Depression: A Home-Based Feasibility and Safety Study

   The investigators propose a single-arm, open-label study to evaluate the effectiveness, safety, tolerability and feasibility of at-home transcranial direct current stimulation (tDCS) as a treatment for depression, particularly in cases where patients have not responded well to traditional therapies…

   Stage

   Not phased

   Ages

   18 to 85

   Site

   UCSD Interventional Psychiatry, San Diego, California

   Run by

   University of California, San Diego

   See if you can join NCT07217223 on ClinicalTrials.gov

3. A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)

   This is a randomized, parallel-group, double-blind, placebo-controlled, monotherapy study to evaluate the efficacy, safety, and tolerability of SPT-300 (GlyphAllo) in adults with major depressive disorder (MDD), with or without anxious distress.

   Stage

   Phase 2

   Ages

   18 to 65

   Site

   Seaport Investigator Site, Chino, California

   Locations

   61 in total

   Run by

   Seaport Therapeutics

   See if you can join NCT07065240 on ClinicalTrials.gov

4. ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response

   The goal of this clinical trial is to learn if ACP-211 can help treat adults with major depressive disorder (MDD) who have not improved with antidepressant therapy (ADT), including those with treatment resistant depression (TRD). The main questions the study aims to answer are: * Does ACP-211 work …

   Stage

   Phase 2

   Ages

   18 to 65

   Site

   Inland Psychiatric Medical Group, Chino, California

   Locations

   26 in total

   Run by

   ACADIA Pharmaceuticals Inc.

   See if you can join NCT07284667 on ClinicalTrials.gov

5. Pilot Study: Establishing Glutamatergic Changes in Rapid Antidepressant Effects of Ketamine

   In the treatment of Major Depressive Disorder (MDD), ketamine can produce rapid but short-lasting improvements in mood. In order to develop a new generation of treatments with rapid and sustained efficacy, a better understanding of the mechanism of action is urgently needed. One candidate mechanism…

   Stage

   EARLY_Phase 1

   Ages

   25 to 65

   Site

   University of Pennsylvania, Philadelphia, Pennsylvania

   Run by

   University of Pennsylvania

   See if you can join NCT06788249 on ClinicalTrials.gov

6. Evaluating Conversational Artificial Intelligence for Depression Management

   The goal of this clinical trial is to evaluate how a conversational method of collecting medical history affects patients' perceptions and experiences compared to clinical care as usual. This conversational AI intake system collects medical history information, can be completed by participants at h…

   Stage

   Not phased

   Ages

   18 to 85

   Site

   George Mason University, Fairfax, Virginia

   Run by

   George Mason University

   See if you can join NCT07105397 on ClinicalTrials.gov

7. A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression

   In this study, researchers will learn more about a study drug called DT-101 in participants with Major Depressive Disorder (MDD), a form of depression. The goal of this clinical trial is to learn if DT-101 can treat depression in adults. The effect of DT-101 will be compared to placebo. A placebo l…

   Stage

   Phase 2

   Ages

   18 to 75

   Site

   Draig Clinical Site, Phoenix, Arizona

   Locations

   23 in total

   Run by

   Draig Therapeutics Ltd

   See if you can join NCT07610473 on ClinicalTrials.gov

8. A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

   The purpose of this study is to determine the efficacy, safety and tolerability of CYB003 compared to matching placebo as adjunctive treatment in patients with MDD. For more information about the EMBRACE study, including participating study locations, and to register your interest in learning more …

   Stage

   Phase 3

   Ages

   18 to 85

   Site

   UAB Psychiatry and Behavioral Neurology, Birmingham, Alabama

   Locations

   69 in total

   Run by

   Cybin IRL Limited

   See if you can join NCT06793397 on ClinicalTrials.gov

9. A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression

   The goal of this clinical trial is to learn if DT-101 can treat depression in adults. The effect of DT-101 will be compared to placebo. Subjects will attend the clinic every couple of weeks complete general health checks and complete questionnaires.

   Stage

   Phase 2

   Ages

   18 to 75

   Site

   Draig Clinical Site, Bentonville, Arkansas

   Locations

   43 in total

   Run by

   Draig Therapeutics Ltd

   See if you can join NCT07300969 on ClinicalTrials.gov

10. Home-Based tDCS Treatment Of Major Depressive Disorder

    The REACH-tDCS study will evaluate the safety and efficacy of a noninvasive, at-home self-administered Sooma tDCS brain stimulation treatment for Major Depressive Disorder. The study uses randomized, blinded, placebo controlled design. The participants are assessed with video interviews and self-re…

    Stage

    Not phased

    Ages

    22 to 70

    Site

    Curavit Clinical Research (virtual study site), Boston, Massachusetts

    Run by

    Sooma Medical Inc

    See if you can join NCT06976697 on ClinicalTrials.gov

11. A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)

    The goal of this clinical trial is to learn if a drug called TNX-102 SL works to treat moderate to severe major depressive disorder in adults. It will also learn about the safety of TNX-102 SL. The main questions it aims to answer are: Does TNX-102 SL improve depression symptoms according to a depr…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Clinical Neuroscience Solutions Inc. - Orlando, Orlando, Florida

    Locations

    25 in total

    Run by

    Tonix Pharmaceuticals, Inc.

    See if you can join NCT07621237 on ClinicalTrials.gov

12. Mechanisms Of Orbitofrontal Stimulation in Depression

    The orbitofrontal cortex (OFC), a region involved in emotional regulation, decision making, and reward processing, is a key area linked to antidepressant response. This study tests whether noninvasive stimulation of the OFC using transcranial magnetic stimulation (TMS) can improve depressive sympto…

    Stage

    Not phased

    Ages

    18 to 65

    Site

    Beth Israel Deaconess Medical Center, Boston, Massachusetts

    Run by

    Subha Subramanian

    See if you can join NCT07230990 on ClinicalTrials.gov

13. Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder

    This study will evaluate the efficacy and safety of SPN-821 in adults with major depressive disorder

    Stage

    Phase 2

    Ages

    18 to 70

    Site

    Collaborative Neuroscience Network, Garden Grove, California

    Run by

    Supernus Pharmaceuticals, Inc.

    See if you can join NCT07226661 on ClinicalTrials.gov

14. Accelerated Intermittent Theta Burst Stimulation for Adolescent and Young Adult Depression With Elevated Suicide Risk

    The goal of this clinical trial is to learn if a fast-acting brain stimulation treatment called transcranial magnetic stimulation (TMS) can help people with depression and suicidal thoughts. The treatment is non-invasive (does not involve surgery or medications), is given over 5 days, and uses brai…

    Stage

    Not phased

    Ages

    15 to 25

    Site

    UC Davis Medical Center, Sacramento, California

    Run by

    University of California, Davis

    See if you can join NCT07025720 on ClinicalTrials.gov

15. Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder

    The purpose of this study is to determine the efficacy and safety of milsaperidone compared to placebo as adjunctive therapy in patients with Major Depressive Disorder

    Stage

    Phase 3

    Ages

    18 to 65

    Site

    Vanda Investigational Site, Phoenix, Arizona

    Locations

    38 in total

    Run by

    Vanda Pharmaceuticals

    See if you can join NCT06830044 on ClinicalTrials.gov

16. The Role of mGluR5 in CBT-I

    This is mechanistic clinical trial that evaluates the role of one of the glutamate receptors (mGluR5) in cognitive behavioral therapy for insomnia (CBT-I) as a common pathway in improving sleep and depression.

    Stage

    Phase 4

    Ages

    18 and older

    Site

    Stony Brook University: Dept of Psychiatry, Stony Brook, New York

    Run by

    Stony Brook University

    See if you can join NCT07076342 on ClinicalTrials.gov

17. Improving Outcomes in Adolescent Inpatient Depression With Deep Transcranial Magnetic Stimulation

    Evaluate the feasibility, safety, and preliminary efficacy of deep Transcranial Magnetic Stimulation (dTMS) as an adjunctive treatment for adolescents hospitalized with major depressive disorder (MDD).

    Stage

    Not phased

    Ages

    14 to 18

    Site

    Cincinnati Childrens Hospital Medical Center, Cincinnati, Ohio

    Run by

    Children's Hospital Medical Center, Cincinnati

    See if you can join NCT07217444 on ClinicalTrials.gov

18. Neurofeedback to Treat Depression - 2

    This study tests the efficacy of a new psychotherapeutic strategy for reducing negative attention bias (and therefore depression severity) in participants with MDD. This real-time fMRI neurofeedback therapy uses cloud-based pattern classification to decode a patient's attentional state and dynamica…

    Stage

    Not phased

    Ages

    18 to 65

    Site

    Center for Neuromodulation in Depression and Stress, Philadelphia, Pennsylvania

    Run by

    University of Pennsylvania

    See if you can join NCT07159061 on ClinicalTrials.gov

19. Orexin Antagonism for Suicide Risk: A Proof-of-Concept Clinical Trial

    The goal of this proof-of-concept clinical trial is to evaluate the initial safety, feasibility, and tolerability of the orexin mixed antagonist suvorexant in a sample of veteran adults with Major Depressive Disorder and elevated suicide risk. The main question it aims to answer is: Is Suvorexant s…

    Stage

    Phase 2

    Ages

    18 to 70

    Site

    James J. Peters Veterans Affairs Medical Center, The Bronx, New York

    Run by

    Marianne Goodman

    See if you can join NCT06854224 on ClinicalTrials.gov

20. PET Imaging Using the Tracer [18F]VAT to Assess the Antidepressant Effect of Nicotine.

    In the brain, certain nerve cells communicate using a chemical called acetylcholine. Acetylcholine is thought to be important for several functions including mood, memory and wakefulness. The purpose of this study is to explore the role of these nerve cells in depression. Also, we would like to und…

    Stage

    Phase 4

    Ages

    18 to 65

    Site

    Stony Brook University: Dept of Psychiatry, Stony Brook, New York

    Run by

    Stony Brook University

    See if you can join NCT07095205 on ClinicalTrials.gov

21. Cognitive Rehabilitation for Veterans With MDD-related Cognitive Functioning Deficits

    Individuals with depression often describe difficulties with memory, attention, concentration, and overall cognitive functioning, which can persist even after mood episodes get better, and can affect treatment and health outcomes. The primary objective of this pilot clinical trial is to evaluate th…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Portland VA Medical Center, Portland, Oregon

    Run by

    Portland VA Medical Center

    See if you can join NCT06728774 on ClinicalTrials.gov